Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action

Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established....

Full description

Saved in:
Bibliographic Details
Sonstige:
Year of Publication:2022
Language:English
Physical Description:1 electronic resource (206 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 04224nam-a2201069z--4500
001 993562964604498
005 20231214133656.0
006 m o d
007 cr|mn|---annan
008 202210s2022 xx |||||o ||| 0|eng d
020 |a 3-0365-5222-7 
035 |a (CKB)5670000000391619 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/93214 
035 |a (EXLCZ)995670000000391619 
041 0 |a eng 
100 1 |a Allison, Simon J  |4 edt 
245 1 0 |a Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action 
246 |a Novel Anti-cancer Agents and Cellular Targets and Their Mechanism 
260 |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2022 
300 |a 1 electronic resource (206 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established. It is apparent that inherent and acquired drug resistance are major challenges with molecular-targeted agents and that on- as well as off-target side effects can still occur. Other issues include drug metabolism by the body and safely supplying a sufficient amount of active drug to the tumor cells. There is a clear and urgent need for new molecular targets and drugs that specifically target cancer cells in different ways to existing approved drugs. This book, through a collection of eight research articles and two review articles from the Biomedicines themed Special Issue ‘Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism(s) of Action’, provides a snapshot of some of the diverse and exciting research approaches being taken by the cancer research community in trying to address some of these therapeutic challenges. 
546 |a English 
650 7 |a Technology: general issues  |2 bicssc 
650 7 |a History of engineering & technology  |2 bicssc 
653 |a microtubule acetylation 
653 |a triple-negative breast cancer 
653 |a anti-cancer agent 
653 |a apoptosis 
653 |a K562 
653 |a 8-hydroxydaidzein 
653 |a autophagy 
653 |a BCR-ABL 
653 |a MAPK 
653 |a NF-κB 
653 |a c-myc 
653 |a RNA interference 
653 |a siRNA 
653 |a oncogene 
653 |a gene silencing 
653 |a expression 
653 |a nanosystems 
653 |a Cytochrome P450 
653 |a CYP1A1 
653 |a CYP1B1 
653 |a CYP2W1 
653 |a breast cancer 
653 |a prodrug 
653 |a bioprecursor 
653 |a duocarmycin 
653 |a phortress 
653 |a AQ4N 
653 |a 5-FU resistance 
653 |a colorectal cancer 
653 |a drug repurposing 
653 |a Genomics of Drug Sensitivity in Cancer 
653 |a Connectivity Map 
653 |a anticancer drug 
653 |a B-lactam steroid alkylators 
653 |a synthetic lethality 
653 |a poly (ADP-ribose) polymerase inhibitors 
653 |a ovarian cancer 
653 |a hybrid steroidal alkylating agents 
653 |a migration 
653 |a invasion 
653 |a glioblastoma 
653 |a CCN1 
653 |a mesenchymal-amoeboid transition 
653 |a biomarker 
653 |a HepG2 
653 |a Huh7 
653 |a isatin sulfonamides 
653 |a angiogenesis 
653 |a cancer hallmarks 
653 |a molecular docking 
653 |a EGFR tyrosine kinase inhibitor 
653 |a photon upconversion 
653 |a triplet-triplet annihilation 
653 |a in vivo imaging 
653 |a PLGA 
653 |a nanoparticles 
653 |a affibody molecule 
653 |a human epidermal growth factor receptor 3 (HER3) 
653 |a BxPC-3 
653 |a emtansine 
653 |a DM1 
653 |a albumin binding domain 
653 |a affibody drug conjugate (AffiDC) 
776 |z 3-0365-5221-9 
700 1 |a Allison, Simon J  |4 oth 
906 |a BOOK 
ADM |b 2023-12-15 06:02:20 Europe/Vienna  |f system  |c marc21  |a 2022-11-05 21:33:14 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5340568990004498&Force_direct=true  |Z 5340568990004498  |b Available  |8 5340568990004498